Skip to main content
ScholarsBetaWeill Cornell Medicine
This profile is being populated. Some content may not yet be available. See Medicine for additional information.

Clinical research

7 studies

Active

3 studies
  • PI
    A Phase 2 Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1
    PHASE2 · Gilead Sciences, Inc. · OPEN TO ACCRUAL (as of 2026)
    HIV-1-infection
    NCT07645287
  • PI
    A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
    PHASE3 · Gilead Sciences, Inc. · OPEN TO ACCRUAL (as of 2024)
    HIV-1-infection
    NCT06630286
  • PI
    A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
    PHASE3 · Gilead Sciences, Inc. · OPEN TO ACCRUAL (as of 2024)
    HIV-1-Infection
    NCT06630299
Completed & closed trials (4)
  • PI
    Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1
    PHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2026)
    HIV-1-infection
    NCT06333808
  • PI
    An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
    PHASE2; PHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2026)
    HIV-1-Infection
    NCT06544733
  • PI
    An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens
    PHASE2; PHASE3 · Gilead Sciences, Inc. · CLOSED TO ACCRUAL (as of 2022)
    HIV-1-infection
    NCT05502341
  • PI
    A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
    PHASE2 · Gilead Sciences, Inc. · CLOSED TO ACCRUAL (as of 2021)
    HIV-1 Infection
    NCT05052996